Therapeutic Area

GLP-1

Therapeutic area intelligence for GLP-1 with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

StrategyJune 16, 2026

In clinical trials, Foundayo demonstrated significant weight loss in women across all stages of menopause, with losses up to 30.4 lbs.

CompetitiveJune 16, 2026

Foundayo (orforglipron) demonstrated a 57.1% greater reduction in A1C and significant weight loss compared to oral semaglutide in pivotal trials.

CompetitiveJune 16, 2026

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

CompetitiveJune 16, 2026

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

No catalysts indexed for this entity yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.